Supernus Pharmaceuticals Basic EPS 2011-2024 | SUPN
Supernus Pharmaceuticals basic eps from 2011 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
| Supernus Pharmaceuticals Annual Basic EPS |
| 2023 |
$0.02 |
| 2022 |
$1.13 |
| 2021 |
$1.01 |
| 2020 |
$2.41 |
| 2019 |
$2.16 |
| 2018 |
$2.13 |
| 2017 |
$1.13 |
| 2016 |
$1.84 |
| 2015 |
$0.29 |
| 2014 |
$-0.26 |
| 2013 |
$-2.90 |
| 2012 |
$-2.72 |
| 2011 |
$31.39 |
| 2010 |
$-26.38 |
| Supernus Pharmaceuticals Quarterly Basic EPS |
| 2024-06-30 |
$0.36 |
| 2024-03-31 |
$0.00 |
| 2023-12-31 |
$0.02 |
| 2023-09-30 |
$-0.29 |
| 2023-06-30 |
$-0.02 |
| 2023-03-31 |
$0.31 |
| 2022-12-31 |
$0.47 |
| 2022-09-30 |
$0.03 |
| 2022-06-30 |
$0.15 |
| 2022-03-31 |
$0.48 |
| 2021-12-31 |
$0.04 |
| 2021-09-30 |
$0.41 |
| 2021-06-30 |
$0.45 |
| 2021-03-31 |
$0.11 |
| 2020-12-31 |
$0.58 |
| 2020-09-30 |
$0.76 |
| 2020-06-30 |
$0.66 |
| 2020-03-31 |
$0.41 |
| 2019-12-31 |
$0.64 |
| 2019-09-30 |
$0.55 |
| 2019-06-30 |
$0.62 |
| 2019-03-31 |
$0.35 |
| 2018-12-31 |
$0.49 |
| 2018-09-30 |
$0.54 |
| 2018-06-30 |
$0.59 |
| 2018-03-31 |
$0.51 |
| 2017-12-31 |
$0.27 |
| 2017-09-30 |
$0.31 |
| 2017-06-30 |
$0.34 |
| 2017-03-31 |
$0.21 |
| 2016-12-31 |
$0.28 |
| 2016-09-30 |
$1.25 |
| 2016-06-30 |
$0.21 |
| 2016-03-31 |
$0.10 |
| 2015-12-31 |
$0.14 |
| 2015-09-30 |
$0.08 |
| 2015-06-30 |
$0.05 |
| 2015-03-31 |
$0.02 |
| 2014-12-31 |
$0.10 |
| 2014-09-30 |
$-0.06 |
| 2014-06-30 |
$0.08 |
| 2014-03-31 |
$-0.38 |
| 2013-12-31 |
$-0.63 |
| 2013-09-30 |
$-0.78 |
| 2013-06-30 |
$-0.89 |
| 2013-03-31 |
$-0.60 |
| 2012-12-31 |
$4.49 |
| 2012-09-30 |
$-0.55 |
| 2012-06-30 |
$-0.61 |
| 2012-03-31 |
$-6.05 |
| 2011-12-31 |
$40.14 |
| 2011-09-30 |
$-6.64 |
| 2011-06-30 |
$-5.17 |
| 2011-03-31 |
$-7.48 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.771B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
